Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that, as part of its ongoing efforts to lower operating expenses, the Company has entered into an agreement to terminate its lease agreement pertaining to the Company’s headquarters in San Carlos, CA, which represented approximately $13 million of annual expenditures. In addition, Herb Cross, Chief Financial Officer, will depart the Company on September 22, 2023, to pursue an external opportunity. Mr. Cross will continue to support the Company as a consultant through the first quarter of 2024. John Orwin, Chief Executive Officer of the Company, will assume the role of principal financial officer and Rick Ruiz, Vice President, Finance of the Company, will assume the role of principal accounting officer going forward.
Related news for (BCEL)
- BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
- BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
- Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
- Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
- Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives